Clinical Trial

An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple cohort study enrolling adults, pediatric and infant participants with Vanishing White Matter disease. Participants will attend regular visits during the course of the study and complete medical assessments, blood tests, questionnaires, and be evaluated for side effects.
Protocol Amendment History 1 change
minor Completion pushed: 2029-11 -> 2035-10 2026-07-02
Trial Details
NCT Number NCT05757141
Lead Sponsor Calico Life Sciences LLC
Conditions Vanishing White Matter Disease
Enrollment 50 participants
Start Date 2023-03-13
Primary Completion 2027-11 (estimated)
Study Completion 2035-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-01